Ind-Swift Ltd.
Snapshot View

10.05 0.00

18 May 2022, 04:00:00 PM
Volume: 2,197

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.indswift.com
Market Cap 54.44 Cr.
Enterprise Value(EV) 1,031.90 Cr. 2021-09
Financial Indicators
Earnings per share (EPS) -5.91 Trailing Twelve Months Ending 2021-12
Price-Earning Ratio (PE) - Trailing Twelve Months Ending 2021-12
Industry PE 28.96 Trailing Twelve Months Ending 2021-12
Book Value / Share -131.03 Trailing Twelve Months Ending 2021-12
Price to Book Value -0.08 Calculated using Price: 10.05
Dividend Yield 0.00 Period Ending 2021-03
No. of Shares Subscribed 5.42 Cr. 54,164,653 Shares
FaceValue 2
Company Profile

Ind-Swift Limited was incorporated as a public limited company on June 6, 1986 under the Companies Act 1956.It is the flagship company of India based Ind Swift Group. Ind-Swift Limited is a north India based pharmaceutical company.

Ind Swift Group is a legendary forename in the world Class Pharmaceutical Industry who has broaden its horizons by plucking profound & sparkling footprints on multifarious diversified fronts, whilst going steadily and surely, scripting a success story filled with enviable milestones and pioneering breakthroughs and has subsequently emergent as a group with an annual turn over of 1000 Crore.

Manufacturing of Pharmaceutical finished dosage are carried out at 7 state-of-the art manufacturing facilities which are second to the none are duly certified and approved by WHO GMP, spread over an area of 12, 00, 000 sq. ft. with manufacturing capacities confirming to stringent TGA/MHRA approvals; possessing an installed capacities of 3 billion units comprising tablets, capsules, ointments, injectables, liquids & dry syrup (all latest formulations with a marketing network.

Business areas of the company are:

Ind-Swift manufactures and markets finished dosage forms, through its different divisions, focusing on the needs of various therapeutic segments. The divisions include the following:Super Speciality, Animal Division, Daignozis, Institutions, Agile, Bio Sciences, Ethical, Health Care, Max Care, Mega care, Neuro and Resurgence

The company is also in health Publications- With the maiden issue in September, 2002; Ind-Swift’s Health Publication TRENDZ brings the latest in medical field to the medical fraternity. Routinely published four times a year, each issue of TRENDZ is devoted to important contemporary healthcare issues and medical issues of a particular specialty.

Ind Swift is known for it's reverse engineering ability with highly focused R & D capabilities (duly approved by Department of Science & Technology, Govt. of India) and is equipped with state-of-the-art equipment, facilities and talented pool of scientists and researchers.

  • A well accepted expertise in NDDS, in India and the world over.
  • A US patent for Clarie OD, with a market size of $300 million.
  • Another patent for Fexofenadine ODT with a market size of $2.5 billion.
  • Development of 10 new molecules with a market size of $6 billion.

Ind Swift’s efforts and achievements in taste masking of macrolides was India's first and remains the only feat of its kind in the country. The R &D department is also involved in creating international opportunities and alliances for CRAMS business, contributing significantly to the company's profitability. It also offers complete support to international partners for preparing and filing dossiers for finished dosages. By taking giant strides on roads less traveled, Ind-Swift has become one of India's fastest growing pharmaceutical companies.

Ind Swift has radianced up in infrastructures business in the name and style of “Ind Swift Infrastructures and developers Ltd, and has come up with a multi crore project named “Regalia Towers”, of course a society with 2 bedroom /3 bedroom flats and penthouses owing a mystique which is exemplary in itself which not only reflects a diversified transformative spell to infrastructures front but a unique state of art with the best of specifications also. In infrastructures, Ind Swift plans to be emergent with motels & Resorts project in the upcoming phases.

Awards/ Achievements

  • Ranked as one of the most promising pharmaceutical group in India by Express Pharma Pulse.
  • All India achievers award as legend in Business house category.
  • An ISO 9001, 2000 company.
  • Achieved Pharma Pulse award as fastest growing & most promising pharmaceutical company for three successive years.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
1 Week
+6.12%
1 Month
-16.39%
3 Month
-20.36%
6 Month
-14.76%
1 Year
+83.39%
2 Year
+390.24%
5 Year
+30.69%
10 Year
-59.56%
9 years 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03
Return on Equity (%) -55.75 -112.51
Return on Capital Employed (%) -3.10 -4.27 -10.41 -20.35 -56.22 -10.31 3.37 5.82 7.19
Return on Assets (%) -7.48 -8.26 -11.09 -17.47 -42.12 -8.45 1.35 -3.19 -4.68

Balance Sheet View Details

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2021-09* Rs. Cr.
Shh. Funds 217 108 -40 -239 -611 -679 -677 -713 -695 -704
Non Curr. Liab. 609 596 549 679 672 694 659 661 661 645
Curr. Liab. 581 686 718 621 608 598 616 654 706 708
Minority Int.
Equity & Liab. 1,407 1,390 1,228 1,061 669 613 598 602 672 649
Non Curr. Assets 519 506 469 439 463 427 405 373 406 397
Curr. Assets 843 851 738 612 206 186 194 229 265 252
Misc. Exp. not W/O 45 33 21 10
Total Assets 1,407 1,390 1,228 1,061 669 613 598 602 672 649

Profit Loss View Details

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2021-12 Rs. Cr. TTM
Net Sales 393 570 417 304 263 270 289 330 356 386
Other Income 6 13 2 13 14 15 8 22 15 17
Total Income 399 583 419 317 277 284 297 352 371 403
Total Expenditure -416 -604 -487 -461 -328 -264 -278 -306 -315 -351
PBIDT -16 -21 -68 -144 -52 21 19 46 57 52
Interest -86 -77 -40 -19 -16 -11 -4 -35 -52 -51
Depreciation -18 -26 -39 -36 -36 -35 -34 -34 -33 -32
Taxation 10 9 2 0 -1 -1 -2 0 -1
Exceptional Items -260 -28 27 6 -1 0
PAT -111 -116 -145 -200 -364 -54 8 -19 -30 -32
Adjusted EPS -24 -23 -29 -40 -67 -10 2 -4 -6 -6

Cash Flow View Details

Particulars 10 years 2012-06 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Cash Fr. Operatn. 94 -146 103 86 -106 7 1 43 35 77
Cash Fr. Inv. -184 -28 -14 -6 -4 -4 -3 -14 -11 -17
Cash Fr. Finan. 99 146 -89 -81 110 -11 -4 -13 -26 -48
Net Change 9 -28 0 -1 0 -8 -5 16 -3 12
Cash & Cash Eqvt 46 18 18 17 17 9 4 20 17 29

Shareholding Pattern View Details

9 Qtrs 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%) 2021-09 (%) 2021-12 (%) 2022-03 (%)
Promoter 55.55 55.55 55.55 55.55 55.55 55.55 55.55 55.55 55.58
Public 44.45 44.45 44.45 44.45 44.45 44.45 44.45 44.45 44.42
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 73.46 73.46 73.46 73.46 73.46 73.46 73.46 73.46 73.43

Announcements View Details

Mon, 16 May 2022
Board Meeting Intimation for Consideration Of Inter-Alia The Standalone Audited Financial Results For Q4 And Financial Year Ended 31St March 2022.
IND-SWIFT LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2022 inter alia to consider and approve And take on record the Standalone Audited Financial Results of the Company for the Fourth Quarter (Q4) and Financial Year ended March 31 2022.
Sat, 14 May 2022
Announcement under Regulation 30 (LODR)-Acquisition
Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 this is to inform the exchange that the company has registered a wholly owned subsidiary (WOS) in Republic of Kenya under the name of INDSWIFT INDIA LIMITED on 13th May 2022. The disclosures under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9 2015 is enclosed as Annexure - I to this intimation.
Sat, 30 Apr 2022
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Format of Initial Disclosure to be made by an entity identified as a Large Corporate.

Sr. No. Particulars Details
1Name of CompayIND-SWIFT LTD.
2CINL24230CH1986PLC006897
3 Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr) 615.90
4Highest Credit Rating during the previous FY ICRA-D
4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)ICRA LIMITED
5Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the frameworkBSE


We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No



Name of the Company Secretary: company in process of appointment of CS
Designation: .
EmailId: companysec@indswift.com
Name of the Chief Financial Officer: Arun Seth
Designation: General Manager Accounts and Finance
EmailId: arunseth@indswift.com

Date: 30/04/2022

Note: In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.

Technical Scans View Details

Wed, 18 May 2022
High Delivery Percentage High Delivery Percentage
Making Higher Highs for 3 days Making Higher Highs for 3 days
Increasing Relative Strength - Sectoral Index Increasing Relative Strength - Sectoral Index
High Decrease 1 Month High Decrease 1 Month
High Decrease 3 Months High Decrease 3 Months

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 215,700.21 899.00 +0.8%
Divi's Laboratories Ltd. 115,623.51 4,355.45 +1.2%
Cipla Ltd. 76,889.38 953.00 +1.6%
Dr. Reddy's Laboratories Ltd. 65,126.60 3,913.25 +0.2%
Apollo Hospitals Enterprise Ltd. 53,689.19 3,734.00 -2.1%
Gland Pharma Ltd. 51,396.43 3,122.95 +0.6%
Piramal Enterprises Ltd. 47,255.41 1,980.00 -0.2%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 33.47 899.00 +0.8%
Divi's Laboratories Ltd. Consolidated 2021-12 45.03 4,355.45 +1.2%
Cipla Ltd. Consolidated 2022-03 30.55 953.00 +1.6%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-12 24.64 3,913.25 +0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-12 47.37 3,734.00 -2.1%
Gland Pharma Ltd. Consolidated 2021-12 43.33 3,122.95 +0.6%
Piramal Enterprises Ltd. Consolidated 2021-12 38.03 1,980.00 -0.2%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 4.17 899.00 +0.8%
Divi's Laboratories Ltd. Consolidated 2021-12 10.67 4,355.45 +1.2%
Cipla Ltd. Consolidated 2022-03 3.69 953.00 +1.6%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-12 3.39 3,913.25 +0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-12 9.70 3,734.00 -2.1%
Gland Pharma Ltd. Consolidated 2021-12 7.48 3,122.95 +0.6%
Piramal Enterprises Ltd. Consolidated 2021-12 1.33 1,980.00 -0.2%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 0.08 899.00 +0.8%
Divi's Laboratories Ltd. Consolidated 2021-03 0.00 4,355.45 +1.2%
Cipla Ltd. Consolidated 2021-03 0.10 953.00 +1.6%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 3,913.25 +0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 0.62 3,734.00 -2.1%
Gland Pharma Ltd. Consolidated 2021-03 0.00 3,122.95 +0.6%
Piramal Enterprises Ltd. Consolidated 2021-03 1.16 1,980.00 -0.2%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 899.00 +0.8%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 4,355.45 +1.2%
Cipla Ltd. Consolidated 2021-03 14.13 953.00 +1.6%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 3,913.25 +0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,734.00 -2.1%
Gland Pharma Ltd. Consolidated 2021-03 20.97 3,122.95 +0.6%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 1,980.00 -0.2%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 899.00 +0.8%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 4,355.45 +1.2%
Cipla Ltd. Consolidated 2021-03 14.13 953.00 +1.6%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 3,913.25 +0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,734.00 -2.1%
Gland Pharma Ltd. Consolidated 2021-03 20.97 3,122.95 +0.6%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 1,980.00 -0.2%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 33,498.14 899.00 +0.8%
Divi's Laboratories Ltd. Consolidated 2021-03 6,969.40 4,355.45 +1.2%
Cipla Ltd. Consolidated 2021-03 19,159.59 953.00 +1.6%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 3,913.25 +0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 10,560.00 3,734.00 -2.1%
Gland Pharma Ltd. Consolidated 2021-03 3,462.88 3,122.95 +0.6%
Piramal Enterprises Ltd. Consolidated 2021-03 12,809.35 1,980.00 -0.2%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 2,284.68 899.00 +0.8%
Divi's Laboratories Ltd. Consolidated 2021-03 1,984.29 4,355.45 +1.2%
Cipla Ltd. Consolidated 2021-03 2,401.30 953.00 +1.6%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 3,913.25 +0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 136.00 3,734.00 -2.1%
Gland Pharma Ltd. Consolidated 2021-03 996.96 3,122.95 +0.6%
Piramal Enterprises Ltd. Consolidated 2021-03 1,074.43 1,980.00 -0.2%